Investors

Overview

Coherus is a late-stage biologics platform company focused on the global biosimilar market. Headquartered in the San Francisco Bay Area and composed of a team of industry veterans with decades of experience in pioneering biologics companies, our goal is to become a global leader in the biosimilar market by leveraging our team’s collective expertise in key areas such as process science, analytical characterization, protein production and clinical-regulatory development. Our commercialization partnerships include global pharmaceutical companies in Europe, Asia and Latin America.

Recent News
10/09/18
REDWOOD CITY, Calif. , Oct. 09, 2018 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that effective October 8, 2018 , the compensation committee of the company’s board of directors granted 65 new employees options to purchase an aggregate of 542,000 shares of the
09/25/18
REDWOOD CITY, Calif. , Sept. 25, 2018 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced the European Commission (EC) has granted marketing authorization to UDENYCA™ (formerly CHS-1701), a pegfilgrastim (Neulasta®) biosimilar.
09/21/18
REDWOOD CITY, Calif. , Sept. 21, 2018 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that effective September 20, 2018 , the compensation committee of the company’s board of directors granted 6 new employees and a Vice President, Corporate Communications and Public
09/17/18
REDWOOD CITY, Calif. , Sept. 17, 2018 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that senior management will be presenting at the 2018 Cantor Global Healthcare Conference being held in New York on Tuesday, October 2, 2018 at 8:00 am ET .
Upcoming Events
There are currently no events scheduled.

Receive E-mail Alerts

Click here to receive e-mail alerts whenever Coherus Biosciences Inc posts new information to the site.

 

Copyright West LLC. Minimum 15 minutes delayed.